Calls
3
Michael Yee
Senior Pharma and Biotech Analyst, UBS
Win Rate
100.0%
return
+1.3%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 01
$148.47
+0.9%
Yee is super bullish on Merck because it is transforming from an old sleepy pharma with a big patent cliff into a growth company, which he thinks supports multiple expansion. He points to multiple upcoming portfolio catalysts, including the Merck-Moderna cancer vaccine and a new ADC/sac-TMT cancer drug later this year.
Pharma & Biotech
Long
Sep 01
$205.80
+2.5%
Yee also likes Revolution Medicines. Its breakthrough pancreatic cancer drug is continuing to make a big impact in lung cancer, making it another major story and an attractive way to play the pharma innovation theme.
Pharma & Biotech
Long
Sep 01
$162.50
+0.5%
Michael Yee says UBS has been quite bullish on pharma/biotech because drug pricing negotiations are reasonable rather than dramatic overhauls, removing policy overhang and uncertainty. He also sees strong M&A, underappreciated R&D and innovation, cheap valuations, and charts starting to break out, with the group potentially acting as an anti-AI trade.
Thematic ETFs
Showing 3 of 3 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Michael Yee has 3 trade ideas tracked on Buzzberg across 3 tickers since September 2026. Most covered: MRK, XBI, RVMD.
